John Kelly summarizes a recent paper published in JAMA that describes the benefits of robotic surgery versus open cystectomy.
Matt Galsky and Tom Powles take the FDA and EMA approach respectively concerning adjuvant nivolumab for bladder cancer.
Cisplatin-based combination chemotherapy is considered standard of care in mUC, but many patients are deemed ineligible.
Jonathan Rosenberg discusses what happened in the world of bladder cancer during 2021 and what to look out for in 2022.
Dr. Arjun Balar discusses bladder cancer, clinical trials involving pembrolizumab, and his career transition.
Dr. Sarmad Sadeghi discusses exciting data about a novel compound in urothelial cancer with Brian and Tom.
Join the debate around pembrolizumab monotherapy in initial treatment of cisplatin-ineligible metastatic urothelial cancer.
Matt Gowski takes a deeper dive into the phase 2 data of neoadjuvant chemo/nivolumab in muscle-invasive bladder cancer.
The Uromigos and Andrea Necchi have a wide-ranging discussion of 3 interesting neoadjuvant IO-based phase 2 trials.
Arjun Balar explains why, despite a negative trial, T cell stimulation plus checkpoint inhibition may warrant future study.
Dr. Lydia Makaroff, Vice President of the World Bladder Cancer Patient Coalition, discusses key issues for bladder cancer.
Dr. Andrea Apollo discusses highlights from the ODAC meeting regarding accelerated approvals for bladder cancer.